T1	Participants 112 126	ovarian cancer
T2	Participants 350 378	Patients with stage IC-IV OC
T3	Participants 1090 1118	820 of 919 patients enrolled
T4	Participants 1120 1246	352 patients with CR received paclitaxel consolidation whereas 155 patients without CR received single-agent crossover therapy
